Tratamiento con infusión subcutánea continua de insulina en pacientes pediátricos con diabetes mellitus tipo 1

Alcol, E. Colino; Capapé, M López; Gomez, Melissa; Alonso‐Blanco, Cristina; Frías, María Martín; Castellanos, Raquel Barrio

doi:10.1016/s1695-4033(06)70004-2

Cited by 6 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall metabolic control was found to be similar in some studies (2,4,5,6,7). Other studies (8,9,10,11,12,13,14,15) found better glycemic control with CSII. In adults, Reznik et al (16) found that CSII was effective, particularly in patients with baseline glycated hemoglobin (HbA1c) of above 8% and may persist until 6-yr follow-up.…”

Section: Introductionmentioning

confidence: 87%

Long-term Efficacy of Insulin Pump Therapy in Children with Type 1 Diabetes Mellitus

Batajoo¹,

Messina²,

Wilson³

2012

Jcrpe

View full text Add to dashboard Cite

Objective: Insulin pumps have been well established for insulin delivery. However, questions about long-term efficacy of insulin pump therapy still remain. We evaluated the long-term efficacy of continuous insulin infusion pump therapy (CSII) in pediatric patients with type 1 diabetes mellitus (T1DM).Methods: This was a retrospective observational study which included 131 patients with T1DM who transitioned to an insulin pump from multiple daily insulin (MDI) injections between 1999 and 2009 and were followed by one endocrinologist. Data were collected from 6 months prior to switching to CSII to 30 months after initiation of CSII and included glycated hemoglobin (HbA1c) and insulin requirement. Of the 131 patients, 45 had complete data consisting of a visit and HbA1c every 6 months for 30 months after transition to CSII and were included for analysis. Results: Mean HbA1c prior to starting the CSII was 8.0 +0.9 %, 7.7 +1.0 % at 6 months and 7.8+1.2 % at 1 yr post initiation of CSII. However, at 30 months, HbA1c increased to 8.0+1.3%. A trend in transient improvement in HbA1c was limited only to those patients >11 yr of age and those requiring >0.75 u/kg/day of insulin at transition and was not seen in those <11 yr of age or those requiring <0.75 u/kg/day and did not persist beyond 1 year. Conclusions: There was no long-term significant difference in glycemic control in patients with CSII as compared to MDI. Conflict of interest:None declared.

show abstract

Section: Introductionmentioning

confidence: 87%

Long-term Efficacy of Insulin Pump Therapy in Children with Type 1 Diabetes Mellitus

Batajoo¹,

Messina²,

Wilson³

2012

Jcrpe

View full text Add to dashboard Cite

show abstract

“…The largest number of comparative therapeutic studies for IP and PEN provide data on the reduction of incidence of severe hypoglycemia in IP patients ( 9 - 11 ).…”

Section: Discussionmentioning

confidence: 99%

Impact of Insulin Delivery Method on Hypoglycemia Incidence in Pediatric Type 1 Diabetes Mellitus Patients

et al. 2017

View full text Add to dashboard Cite

IntroductionInsulin therapy of pediatric patients with type 1 diabetes mellitus (T1DM) is highly demanding due to their dynamic growth, development and different daily life activities.GoalTo determine the optimal insulin delivery method for the prevention of hypoglycemia recorded by continuous monitoring of glucose in patients with insulin pump and PEN.Material and MethodsThe study included patients up to 18 years of age with diagnosed T1DM and treated with insulin pump and by insulin therapy with PEN at the Pediatric Clinic of the Clinical Center in Sarajevo. The study involved 149 patients, and lasted for 3 years. Patients were divided into two groups: group of patients on insulin pump therapy and group on insulin PEN.ResultsThere were 73 patients (49.6%) on insulin pump therapy and 79 patients (52.4%) on the insulin PEN therapy. There was no significant difference in the age between genders nor groups with different insulin application methods. There were no significant differences in the number of anamnestic hypoglycemia in patients with a different mode of insulin application (83.56% vs. 81.58%, p=0.114, F=2.533 < Fk=3.919). The number of hypoglycemia episodes in history is higher with the PEN therapy than in the insulin pump group.ConclusionThe number of anamnesis hypoglycemia as well as hypoglycemia from CGM records did not differ significantly in patients with IP and PEN therapy. The CGM record was significantly more valuable in the presentation of hypoglycemia compared to the history of hypoglycemia in all patients studied. Continuous monitoring of glycemia due to the ability to show glycemia variability and unrecognized hypoglycemia as well as predictive options for long-term metabolic control should be performed for all T1DM patients at least once a year.

show abstract

Comentario al artículo “Tratamiento con infusión subcutánea continua de insulina en pacientes pediátricos con diabetes mellitus tipo 1”

Serra

2007

Anales de Pediatría

View full text Add to dashboard Cite

Tratamiento con infusión subcutánea continua de insulina en pacientes pediátricos con diabetes mellitus tipo 1

Cited by 6 publications

References 27 publications

Long-term Efficacy of Insulin Pump Therapy in Children with Type 1 Diabetes Mellitus

Long-term Efficacy of Insulin Pump Therapy in Children with Type 1 Diabetes Mellitus

Impact of Insulin Delivery Method on Hypoglycemia Incidence in Pediatric Type 1 Diabetes Mellitus Patients

Comentario al artículo “Tratamiento con infusión subcutánea continua de insulina en pacientes pediátricos con diabetes mellitus tipo 1”

Contact Info

Product

Resources

About